By Michael Dabaie
Savara Inc. (SVRA) shares fell 75% to $2.61 Thursday morning.
The orphan lung disease company said Wednesday the IMPALA Phase 3
study of Molgradex to treat autoimmune alveolar pulmonary proteinosis
didn't meet its primary endpoint of alveolar-arterial oxygen gradient.
The study showed statistically significant improvement in the St.
George's Respiratory Questionnaire, a key secondary endpoint, the
The company said it plans to meet with the U.S.
Food and Drug Administration and European Medicines Agency in the coming
months to discuss the data and path forward.
JMP Securities cut Savara to Market Perform from Outperform.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
June 13, 2019 10:44 ET (14:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.